Charles River Laboratories International, Inc. (NYSE:CRL) Receives $214.00 Consensus Price Target from Analysts

Shares of Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) have received an average recommendation of "Reduce" from the fifteen analysts that are covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and two have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $214.00.

A number of research analysts have recently issued reports on CRL shares. TD Cowen lifted their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a report on Monday, November 11th. CLSA cut Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price objective for the company. in a research report on Monday, November 18th. Bank of America lowered their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research report on Friday, December 13th. Robert W. Baird lowered their price objective on Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating for the company in a research report on Friday, September 20th. Finally, Redburn Atlantic initiated coverage on Charles River Laboratories International in a research report on Monday, October 14th. They issued a "sell" rating and a $151.00 price objective for the company.

Insider Buying and Selling at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the company's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares of the company's stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.30% of the company's stock.

Hedge Funds Weigh In On Charles River Laboratories International

Large investors have recently bought and sold shares of the business. Wolff Wiese Magana LLC acquired a new position in shares of Charles River Laboratories International during the third quarter valued at approximately $32,000. Versant Capital Management Inc raised its holdings in shares of Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after acquiring an additional 150 shares during the last quarter. Assetmark Inc. raised its holdings in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock valued at $37,000 after acquiring an additional 173 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Charles River Laboratories International during the third quarter valued at approximately $59,000. Finally, ORG Wealth Partners LLC acquired a new position in shares of Charles River Laboratories International during the fourth quarter valued at approximately $56,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Stock Up 2.2 %

Shares of NYSE:CRL traded up $4.01 on Monday, reaching $190.13. The company had a trading volume of 670,633 shares, compared to its average volume of 632,662. Charles River Laboratories International has a 52-week low of $176.48 and a 52-week high of $275.00. The firm's 50 day simple moving average is $193.42 and its 200-day simple moving average is $199.44. The firm has a market capitalization of $9.72 billion, a PE ratio of 23.80, a PEG ratio of 5.00 and a beta of 1.38. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same period last year, the business posted $2.72 EPS. The business's revenue was down 1.6% compared to the same quarter last year. As a group, analysts expect that Charles River Laboratories International will post 10.18 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).